1. Home
  2. YDES vs SPRY Comparison

YDES vs SPRY Comparison

Compare YDES & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDES

YD Bio Limited Ordinary Shares

HOLD

Current Price

$4.18

Market Cap

543.0M

Sector

N/A

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$5.46

Market Cap

558.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDES
SPRY
Founded
2013
2015
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
543.0M
558.9M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
YDES
SPRY
Price
$4.18
$5.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$40.00
AVG Volume (30 Days)
174.8K
1.5M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
N/A
$87.40
Revenue Next Year
N/A
$81.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$4.91
52 Week High
$25.00
$13.15

Technical Indicators

Market Signals
Indicator
YDES
SPRY
Relative Strength Index (RSI) 57.16 40.29
Support Level $1.99 $5.04
Resistance Level $5.15 $8.61
Average True Range (ATR) 0.84 0.31
MACD -0.09 0.02
Stochastic Oscillator 49.21 18.84

Price Performance

Historical Comparison
YDES
SPRY

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: